

**From:** [Harris, Paul](#)  
**To:** [NSIR\\_DSP Document Processing Resource](#)  
**Cc:** [Zaleski, Brian](#); [Mossman, Timothy](#)  
**Subject:** ADAMS ADD NEEDED: NRC Staff Information on the Reporting of Dilutes on the NRC FFD Annual D&A e-form  
**Date:** Thursday, January 15, 2015 10:51:32 AM  
**Attachments:** [form\\_665s.docx](#)

---

Please add this email conversation to ADAMS

Thank you,  
Paul

---

**From:** Harris, Paul  
**Sent:** Thursday, January 15, 2015 10:41 AM  
**To:** dolores.adams@exeloncorp.com; ahmed.alobthan@enec.gov.ae; chasity.anderson@ic.fbi.gov; mgansel@tva.gov; david.balatincz@dayzim.com; chbaldr@wcnoc.com; jacleen.barge@dayzim.com; lisa@bartlettinc.com; baumanam@westinghouse.com; paul.benjamin@cbi.com; dsbohline@gmail.com; tlbond@aep.com; david.bonhron@fpl.com; david.book@systemoneservices.com; tommy.brauer@dom.com; josh.brisbine@usa.g4s.com; browermj@inpo.org; dbrune@stpegs.com; rbuckles@curtisswright.com; kevin.buckley@exeloncorp.com; caburkhart@pplweb.com; lbrunette@southernbackgrounds.com; kthenderson@tva.gov; bchambers@scana.com; steve.champlin@midwesttox.com; patti.christopherson@pgnmail.com; ajc@nei.org; jcoleman@endevorllc.com; kevin.concannon@exeloncorp.com; maryanncotten@hotmail.com; michael.covert@enec.gov.ae; hubert.crooms@scana.com; jadavila@energysolutions.com; cara.davis@duke-energy.com; mdeigna@entergy.com; benzito13@gmail.com; dipietron@firstenergycorp.com; sandy.downes@cartwrightdownes.com; duffyt@teenergy.com; stella.dumais@nee.com; ellisag@firstenergycorp.com; vicki.farbo@exeloncorp.com; ajfeuerborn@energy-northwest.com; pfowler@creativeservices.com; egiblin@ashcroftlawfirm.com; mtgulliford@firstenergycorp.com; jgootkind@creativeservices.com; jagorman@pplweb.com; jgracely@curtisswright.com; kjgreer@nuclearfuelservices.com; tmgreer@aep.com; hamiltkn@westinghouse.com; jahansen@energy-northwest.com; jeh@nei.org; Harris, Paul; hwharvey@energy-northwest.com; rhaselden@scana.com; lydia.heatwole@fpl.com; cahoch@wcnoc.com; mahoffman@firstenergycorp.com; edna.holdsworth@dom.com; gary.house@siemens.com; chughes@wisgrp.com; sue.hurst@illinois.gov; dingram@wisgrp.com; rgilbert@endevorllc.com; theresa.jones@aps.com; sojones@wcnoc.com; robertkelm@aol.com; rkelmjr@aol.com; dk@nei.org; sarah.kosanke@midwesttox.com; plackman@ameren.com; alee@ameren.com; jlontin@southernco.com; debra.loudenslager@duke-energy.com; tlovett@southernco.com; adam.lurie@socialintel.com; paul.macuiaba@exeloncorp.com; sandra.mangum@luminant.com; dmatko@bargroup.net; lmf0@pge.com; jneher@ameren.com; mmccrady@ameren.com; edward.porto@aps.com; a.b.basista@constellation.com; jerry.c.phifer@constellation.com; michael.beers@dom.com; ron.orga@dom.com; louwersj@teenergy.com; pskowalewski@duke-energy.com; clrobinson@energy-northwest.com; wgraff@entergy.com; nernt@entergy.com; tstewar@entergy.com; pweaver@entergy.com; jayson.cohen@exeloncorp.com; rob.radulovich@exeloncorp.com; rjwilcosky@firstenergycorp.com; liz\_mcney@fpl.com; john.bellows@xenuclear.com; jack.phelps@xenuclear.com; david.soward@xenuclear.com; darlene.stimart@xenuclear.com; tachapi@nppd.com; anthony.williams@pgnmail.com; jeffrey.defebo@pseg.com; rpmumme@stpegs.com; dntruong@tva.gov; eugene.dyas@luminant.com; david.volkening@luminant.com; jajenek@wcnoc.com; rgleo@southernco.com; jblowery@southernco.com; dlcrawle@southernco.com; ajonesj@entergy.com; edie.boyer@xenuclear.com; lisa.jenson@xenuclear.com; william.kappes@xenuclear.com; john.ott@xenuclear.com; andrew.regnier@xenuclear.com; john.theurer@pseg.com; rseipel@tva.gov; eemurphy@firstenergycorp.com; jbk1@pge.com  
**Cc:** Zaleski, Brian; 'robertkelm'; 'dk@nei.org'; ajc@nei.org; Mossman, Timothy  
**Subject:** NRC Staff Information on the Reporting of Dilutes on the NRC FFD Annual D&A e-form

FFD Professionals,

We had a question from one of your peers on the reporting of dilutes and the conduct of special analyses as required on the Annual Reporting Form for your drug testing program.

Please consider the information below in completing your Annual Reporting Form. If I missed someone on this email distribution, please forward.

Please continue call and emailing us if you need help.

R,  
Paul

---

**From:** Zaleski, Brian  
**Sent:** Wednesday, January 14, 2015 11:43 AM  
**To:** 'Hansen, Julie A.'  
**Cc:** Harris, Paul  
**Subject:** RE: ACTION = Question on the NRC Report

Morning Julie,

Thanks for your question.

The two questions in the Special Analysis section of the Annual Reporting Form for Drug and Alcohol Testing collect information on special analysis testing conducting by your program per 49 CFR 26.163(a)(2).

The first box "Total Number of "Dilute" Specimen Test Results (optional)" is the total number of urine specimens that the HHS-certified laboratory reported with a validity test result of "dilute".

Enter the total number of dilute specimen test results for all specimens tested in the calendar year. Dilute specimen criteria are described in 26.161(e).

The second box "Total Number of "Dilute" Specimen Test Results (Special Analysis Testing conducted)" is the total number of urine specimens where special analysis testing (i.e., LOD testing) was conducted by the HHS laboratory. This number should be ALL specimens tested at LOD (regardless of positive or negative test result). We capture the number of dilute positive results in your Single Positive Test Forms submitted (i.e., you'll submit 3 SPTFs, one for each of the dilute positive results in 2014).

Enter the total number of specimens where special analyses testing was conducted, as permitted in 26.163(a)(2). This information is required by 26.717(b)(2).

I'm unclear about what you're referring to regarding 52 specimens. Did your program receive 52 "dilute" validity test results from the laboratory and only 18 of those specimens met the criteria to test at LOD (i.e., a drug/drug metabolite was present within 50% of the cutoff calibrator concentration at initial testing)?

Please give me a ring, happy to help clear this up with you.

Brian

**Brian Zaleski** | Fitness For Duty Specialist | 301.287.0638 | office: 3WFN 8A9 | [brian.zaleski@nrc.gov](mailto:brian.zaleski@nrc.gov)  
**U.S. Nuclear Regulatory Commission** | Office of Nuclear Security and Incident Response | Security Programs Support Branch

---

**From:** Harris, Paul  
**Sent:** Wednesday, January 14, 2015 11:01 AM  
**To:** Zaleski, Brian  
**Cc:** 'Hansen, Julie A.'  
**Subject:** ACTION = Question on the NRC Report

Brian, this is the email I mentioned to you. May you please respond to Julie, thanks.

Paul

---

**From:** Hansen, Julie A. [<mailto:JAHANSEN@energy-northwest.com>]  
**Sent:** Friday, January 09, 2015 3:08 PM  
**To:** Harris, Paul  
**Subject:** Question on the NRC Report

Paul,

I have a question about the Annual NRC Report. Would it be correct to put in the total of specimens that were Dilute (18) then the total of dilutes that had a positive drug test with the dilute (3)? We sent out a total of 52 but out of those 18 were dilute negative and 3 were dilute positive. I just want to make sure I provide the correct information.

**Substances Tested**

Did your program only test for NRC-required substances AND at the NRC-specified minimum cutoff levels? (Yes / No)

Does your program conduct LOD testing permitted in 26.163(a)(2)? (Yes / No)

**Special Analyses Testing Results**

Total Number of "Dilute" Specimen Test Results (Optional)

Total Number of "Dilute" Specimens (Special Analyses Testing Conducted)

| Substance    | Use Only NRC Cutoff Levels? (Yes / No) | Initial Cutoff | Confirmatory Cutoff | LOD Testing? (Yes / No)                     | Comment (Optional)          |
|--------------|----------------------------------------|----------------|---------------------|---------------------------------------------|-----------------------------|
| Alcohol      | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Not Applicable"/> |                             |
| Cocaine      | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Please Select"/>  | Return to works and dilutes |
| Marijuana    | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Please Select"/>  | Return to works and dilutes |
| Amphetamines | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Please Select"/>  | Return to works and dilutes |
| Opiates      | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Please Select"/>  | Return to works and dilutes |
| PCP          | <input type="text" value="Yes"/>       |                |                     | <input type="text" value="Please Select"/>  | Return to works and dilute  |

**Julie Hansen** / FFD Lead

Energy Northwest /Columbia

☎ 509. 377.8392 / F 509. 377.8550

[JAHANSEN@energy-northwest.com](mailto:JAHANSEN@energy-northwest.com)